$466 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 64 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 146.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | INVESCO QQQ TRcall | $61,510,680 | – | 231,000 | +100.0% | 13.20% | – | |
| Buy | TEVA PHARMACEUTICAL INDS LTDcall | $20,267,376 | +13.6% | 2,222,300 | +0.6% | 4.35% | +75.7% | |
| CRNX | Buy | CRINETICS PHARMACEUTICALS IN | $12,291,085 | -0.1% | 671,644 | +7.2% | 2.64% | +54.4% |
| ALBO | Buy | ALBIREO PHARMA INC | $10,023,323 | +44.2% | 463,828 | +29.2% | 2.15% | +122.9% |
| KZR | Buy | KEZAR LIFE SCIENCES INC | $9,188,446 | -14.3% | 1,305,183 | +4.8% | 1.97% | +32.4% |
| RARE | Buy | ULTRAGENYX PHARMACEUTICAL IN | $8,510,636 | +18.3% | 183,696 | +5.8% | 1.83% | +83.1% |
| SWTX | Buy | SPRINGWORKS THERAPEUTICS INC | $8,235,416 | -4.3% | 316,625 | +5.0% | 1.77% | +48.1% |
| New | ASTRIA THERAPEUTICS INC | $6,988,473 | – | 469,340 | +100.0% | 1.50% | – | |
| New | TOWER SEMICONDUCTOR LTDput | $6,981,120 | – | 161,600 | +100.0% | 1.50% | – | |
| Buy | CINCOR PHARMA INC | $6,509,276 | +66.7% | 529,640 | +345.3% | 1.40% | +157.7% | |
| FIVN | New | FIVE9 INC | $6,446,600 | – | 95,000 | +100.0% | 1.38% | – |
| CNCE | Buy | CONCERT PHARMACEUTICALS INC | $5,856,253 | -8.3% | 1,002,783 | +5.2% | 1.26% | +41.9% |
| XBI | New | SPDR SER TRs&p biotech | $5,810,000 | – | 70,000 | +100.0% | 1.25% | – |
| GNRC | New | GENERAC HLDGS INC | $5,032,995 | – | 50,000 | +100.0% | 1.08% | – |
| MRUS | Buy | MERUS N V | $4,903,882 | -21.9% | 316,993 | +1.2% | 1.05% | +20.8% |
| KNSA | New | KINIKSA PHARMACEUTICALS LTD | $4,603,099 | – | 307,283 | +100.0% | 0.99% | – |
| New | LEONARDO DRS INC | $4,288,418 | – | 335,557 | +100.0% | 0.92% | – | |
| BLU | Buy | BELLUS HEALTH INC NEW | $4,026,649 | -18.0% | 489,860 | +5.4% | 0.86% | +26.9% |
| RIGL | Buy | RIGEL PHARMACEUTICALS INC | $3,418,268 | +33.9% | 2,278,845 | +5.4% | 0.73% | +107.3% |
| New | APELLIS PHARMACEUTICALS INCput | $3,102,600 | – | 60,000 | +100.0% | 0.67% | – | |
| CAMT | New | CAMTEK LTDord | $2,415,600 | – | 110,000 | +100.0% | 0.52% | – |
| STOK | Buy | STOKE THERAPEUTICS INC | $1,741,147 | -13.7% | 188,640 | +20.0% | 0.37% | +33.6% |
| INZY | Buy | INOZYME PHARMA INC | $1,706,311 | -45.8% | 1,625,058 | +38.3% | 0.37% | -16.2% |
| BCAB | New | BIOATLA INC | $1,539,450 | – | 186,600 | +100.0% | 0.33% | – |
| New | MEDIWOUND LTD | $1,017,321 | – | 75,413 | +100.0% | 0.22% | – | |
| AUTL | New | AUTOLUS THERAPEUTICS PLCspon ads | $950,000 | – | 500,000 | +100.0% | 0.20% | – |
| AMAT | New | APPLIED MATLS INC | $827,558 | – | 8,499 | +100.0% | 0.18% | – |
| TBLA | New | TABOOLA.COM LTD | $369,600 | – | 120,000 | +100.0% | 0.08% | – |
| AGLE | New | AEGLEA BIOTHERAPEUTICS INC | $198,333 | – | 440,837 | +100.0% | 0.04% | – |
| DYN | New | DYNE THERAPEUTICS INC | $82,857 | – | 7,149 | +100.0% | 0.02% | – |
| New | 89BIO INCcall | $45,828 | – | 3,600 | +100.0% | 0.01% | – | |
| New | OUTBRAIN INC | $43,976 | – | 12,148 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
| SC 13G | 2023-08-30 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.